Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

被引:104
作者
Seaman, MS
Xu, L
Beaudry, K
Martin, KL
Beddall, MH
Miura, A
Sambor, A
Chakrabarti, BK
Huang, Y
Bailer, R
Koup, RA
Mascola, JR
Nabel, GJ
Letvin, NL
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA
[2] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.79.5.2956-2963.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The development of a human immunodeficiency virus type 1 (HIV-1) vaccine that elicits potent cellular and humoral immune responses recognizing divergent strains of HIV-1 will be critical for combating the global AIDS epidemic. The present studies were initiated to examine the magnitude and breadth of envelope (Env)specific T-lymphocyte and antibody responses generated by vaccines containing either a single or multiple genetically distant HIV-1 Env immunogens. Rhesus monkeys were immunized with DNA prime-recombinant adenovirus boost vaccines encoding a Gag-Pol-Nef polyprotein in combination with either a single Env or a mixture of clade-A, clade-B, and clade-C Envs. Monkeys receiving the multiclade Env immunization developed robust immune responses to all vaccine antigens and, importantly, a greater breadth of Env recognition than monkeys immunized with vaccines including a single Env immunogen. All groups of vaccinated monkeys demonstrated equivalent immune protection following challenge with the pathogenic simian-human immunodeficiency virus 89.6P. These data suggest that a multicomponent vaccine encoding Env proteins from multiple clades of HIV-1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference. This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1.
引用
收藏
页码:2956 / 2963
页数:8
相关论文
共 26 条
[1]   Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa [J].
Bures, R ;
Morris, L ;
Williamson, C ;
Ramjee, G ;
Deers, M ;
Fiscus, SA ;
Abdool Karim, SS ;
Montefiori, DC .
JOURNAL OF VIROLOGY, 2002, 76 (05) :2233-2244
[2]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[3]   Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development [J].
Cao, HY ;
Kanki, P ;
Sankale, JL ;
DiengSarr, A ;
Mazzara, GP ;
Kalams, SA ;
Korber, B ;
Mboup, S ;
Walker, BD .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8615-8623
[4]   Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization [J].
Chakrabarti, BK ;
Kong, W ;
Wu, B ;
Yang, ZY ;
Friborg, J ;
Ling, X ;
King, SR ;
Montefiori, DC ;
Nabel, GJ .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5357-5368
[5]  
CHAKRABARTI BK, UNPUB EXPANDED BREAD
[6]   Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants [J].
Charini, WA ;
Kuroda, MJ ;
Schmitz, JE ;
Beaudry, KR ;
Lin, WY ;
Lifton, MA ;
Krivulka, GR ;
Necker, A ;
Letvin, NL .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :4996-5003
[7]   Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines [J].
Fattom, A ;
Cho, YH ;
Chu, CY ;
Fuller, S ;
Fries, L ;
Naso, R .
VACCINE, 1999, 17 (02) :126-133
[8]   Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines [J].
Ferrari, G ;
Kostyu, DD ;
Cox, J ;
Dawson, DV ;
Flores, J ;
Weinhold, KJ ;
Osmanov, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (14) :1433-1443
[9]   AIDS - Diversity considerations in HIV-1 vaccine selection [J].
Gaschen, B ;
Taylor, J ;
Yusim, K ;
Foley, B ;
Gao, F ;
Lang, D ;
Novitsky, V ;
Haynes, B ;
Hahn, BH ;
Bhattacharya, T ;
Korber, B .
SCIENCE, 2002, 296 (5577) :2354-2360
[10]   Clinical trials of HIV vaccines [J].
Graham, BS .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :207-221